Background and Purpose: Large breast size is associated with an increased risk of late adverse effects after breast conservation surgery and radiotherapy, even when 3D dosimetry is used. The purpose of this study is to test the hypothesis that residual dose inhomogeneity is sufficient to explain the association. Methods: Patients previously treated after breast conservation surgery with whole breast radiotherapy using 3D dosimetry and followed up in the UK FAST hypofractionation trial were selected for this analysis. The residual level of dose inhomogeneity across the whole breast treatment volume was used to test for association between residual dosimetry and post-treatment change in breast appearance at 2 years post-radiotherapy. Results: At 2 years, 201/279 (72%) of women had no change in photographic breast appearance, 61 (22%) had mild change and 17 (6%) had marked change. Breast size and dosimetry were both significantly associated with late effects in univariate analyses, but only breast size remained an independent significant risk factor for change in breast appearance when included in a multiple regression model together with other prognostic factors (p = 0.006 for trend). Conclusion: Large-breasted women are more likely to suffer change in breast size and shape after whole breast radiotherapy delivered using 3D dosimetry, but residual dose inhomogeneity is insufficient to explain the association.
a b s t r a c t
Background and Purpose: Large breast size is associated with an increased risk of late adverse effects after breast conservation surgery and radiotherapy, even when 3D dosimetry is used. The purpose of this study is to test the hypothesis that residual dose inhomogeneity is sufficient to explain the association. Methods: Patients previously treated after breast conservation surgery with whole breast radiotherapy using 3D dosimetry and followed up in the UK FAST hypofractionation trial were selected for this analysis. The residual level of dose inhomogeneity across the whole breast treatment volume was used to test for association between residual dosimetry and post-treatment change in breast appearance at 2 years post-radiotherapy. Results: At 2 years, 201/279 (72%) of women had no change in photographic breast appearance, 61 (22%) had mild change and 17 (6%) had marked change. Breast size and dosimetry were both significantly associated with late effects in univariate analyses, but only breast size remained an independent significant risk factor for change in breast appearance when included in a multiple regression model together with other prognostic factors (p = 0.006 for trend). Conclusion: Large-breasted women are more likely to suffer change in breast size and shape after whole breast radiotherapy delivered using 3D dosimetry, but residual dose inhomogeneity is insufficient to explain the association.
Ó 2011 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology xxx (2011) xxx-xxx
There is retrospective evidence that breast size is a risk factor for late adverse effects following breast conservation surgery and adjuvant radiotherapy for early breast cancer [1] [2] [3] [4] [5] [6] [7] [8] [9] . Body mass index, correlated to breast size and brassiere size, has also been linked to the risk of acute skin reactions and to late cosmesis [10] [11] [12] . Not all studies are confirmatory, but the weight of evidence suggests that the association between the size of the breast and the risk of early and late adverse effects in the breast is real [13] [14] [15] [16] . Analyses are based on assessments of late adverse effects made in clinic or from photographs, focusing on changes in breast size and shape, breast oedema and telangiectasia. Marked acute skin reactions in the inframammary fold of heavy-breasted patients may explain part of the association via an increased risk of consequential late effects.
Suboptimal dosimetry is thought to explain at least part of the association between breast size and risk of late normal tissue damage after radiotherapy delivered using 2D techniques [1, 2, 4, 6, 17] . A cause and effect relationship is supported by the 5-year results of a randomised trial (N = 306) comparing 2D and 3D radiation dosimetry [18] , but not so far by the 2-year results of a larger confirmatory study [19] . Assuming dose distribution matters, it is not known if residual dose inhomogeneity in patients treated using 3D dosimetry explains a significant component of late adverse effects in large breasted women. Other factors associated with late adverse effects, including age [20] , scar visibility, large excision volume, post-operative complications [12] , smoking and adjuvant chemotherapy [11, 21] , appear unlikely to provide an adequate alternative explanation, since they are not all associated with breast size. Against this background, a retrospective analysis has been undertaken to test the hypothesis that residual dose inhomogeneity of whole breast radiotherapy delivered in conformity with ICRU recommendations (95-107% of reference) [22, 23] accounts for a significant part of the association between breast size and risk of late adverse effects. 
Methods

Study population
Patients were selected from those participating in the UK FAST hypofractionation trial, which randomised 915 patients between October 2004 and March 2007 to 25-and 5-fraction regimens of whole breast radiotherapy after primary tumour excision of early breast cancer [24] . Eligibility criteria included age P50 years, invasive breast carcinoma, <3 cm microscopic diameter, complete microscopic resection, negative axillary histology and written informed consent. Women were ineligible for trial entry if they required a tumour bed radiotherapy boost dose or neo-adjuvant/ adjuvant chemotherapy. Patients were randomised (1:1:1) between 50 Gy in 25 fractions of 2.0 Gy over 35 days (Control group), 30 Gy in five fractions of 6.0 Gy or 28.5 Gy in five fractions of 5.7 Gy treating once a week over 29 days (Test groups 1 and 2). Only a subset of the 18 radiotherapy centres participating in the FAST trial had compatible radiotherapy planning systems that allowed importation of data for joint analysis. Patients from the six centres with compatible planning systems were eligible for inclusion in the study.
Virtual simulation and 3D dosimetry in the FAST trial
Participating centres using 3D X-ray computer tomography (CT) imaging were included. Patients were imaged in the supine position using a recommended specialised breast board for immobilisation. Reproducibility of position was achieved by matching orthogonal laser beams with anterior and bilateral skin tattoos. The clinical target volume (CTV) was defined to include soft tissues of the whole breast down to the deep fascia, but not including underlying muscle and ribcage, nor overlying skin and excision scar. The inferior, medial and lateral limits of the breast were localised by inspection and palpation of the breast before CT images were collected. The superior border was defined in relation to the suprasternal notch. The planning target volume (PTV) included these limits to the CTV plus a 1 cm expansion in four radial directions. The radiotherapy plan for all patients was generated using two standard tangential fields with non-divergent posterior beam edges. The recommended maximum lung distance and maximum heart distance in the treatment volume was <2 and <1 cm, respectively. Cardiac shielding, where appropriate, was introduced using a multi-leaf collimator or other shielding technique.
The prescription point was half-way between the anterior lung surface and the skin surface on the perpendicular bisector of the posterior treatment beam edge. The FAST protocol followed guidelines of the International Commission on Radiation Units and Measurements (ICRU) reports 50 (1993) and 62 (1999) recommending dose variation throughout the treated volume between À5% and +7% [22, 23] . If a standard wedged pair was insufficient, full dose compensation was performed using either missing tissue compensators based on outlines or portal images, or intensity modulated fields generated by forward or inverse planning. In practice, a forward-planned multi-leaf collimator (MLC) segment method was the dose compensation technique most commonly employed by participating centres. The body contours were obtained by CT and transferred to the planning system. Standard treatment fields were applied, and dose homogeneity was evaluated. Any hot spots of dose greater than 107% were minimised. A sagittal view through the breast was created with isodose lines greater than 107% displayed, see Fig. 1 . A segment field was added using MLC to shield hot spots. If these were still present, an additional segment was used. The relative weightings of the segment fields tended to be very small (around 5%). Six MV energy X-rays were recommended in the majority of patients, but for patient separations >22 cm, higher energies were considered to optimise dosimetry.
Definition and assessment of late adverse radiation effects in the FAST trial
The primary endpoint of the FAST trial was change in photographic breast appearance at 2 and 5 years post-radiotherapy compared to post-surgical baseline photographs. Photographs (two frontal views of the chest, one with hands on hips and one with arms raised) were prospectively collected under standard conditions. Pairs of photographs (baseline and follow-up) were reviewed by observers blinded to treatment allocation and scored for change in breast appearance according to a three-point graded scale (no change/mild change/marked change) [25] . The START trial confirmed year two to be a valid time point for assessment, given a strong correlation between photographic scores at years two and five [26] .
Assessment of dose-volume histogram (DVH) data for current study
Dosimetry data provided by FAST centres with compatible planning systems for central analysis for this current study were in the DICOMRT or RTOG format. It was not a mandatory trial requirement for participating FAST centres to outline whole breast volumes on CT scans, as already described. In order to carry out the dose-volume histogram (DVH) analysis required for this study, the entire dose cube of each radiotherapy plan was exported into a spreadsheet allowing the DVH data to be calculated for each isodose bin. DVH data were grouped into the following isodose bins: 50-90%, 90-95%, 95-97%, 97-100%, 100-103%, 103-105%, 105-107%, >107%.
Assessment of breast size for current study
A measure of breast volume in cubic centimetres (cc) was estimated using radiotherapy planning X-ray CT images, but since the superior, inferior, medial and lateral limits of the CTV were defined by inspection and palpation, a breast CTV was not calculated. Instead, tissue lying within the 50% isodose line was selected as an appropriate surrogate measure, less dependent than the 95% isodose line on the planning system and on the different X-ray energies selected for treatment. The 50% isodose line included non-target tissues, including ribcage, pectoral muscle and skin, that contribute to late adverse effects scored in the breast, and lung tissue which does not. This measure of breast volume was validated against photographic breast size scored clinically by consensus between three observers applying a three-point graded scale (small, medium, large) to images taken post-surgery and before radiotherapy under standard conditions, as previously described [26, 27] .
Statistical methods
A parameter representing the proportion of breast volume receiving >100% of prescribed dose was created from the dosevolume histogram data. Raw data for absolute breast volume (representing breast size) and percentage volume of breast tissue receiving >100% of prescribed dose were summarised and tested using non-parametric methods (median, interquartile range, Kruskal-Wallis test) as the distributions were skewed. As very few patients had marked change in breast appearance, the mild and marked categories were combined for the analysis to define an endpoint of any change in photographic breast appearance. The 100% reference point did not represent an arbitrary cut-point for the analysis. Higher cut-points were considered, but these sampled a more limited part of the dose-volume distribution. It was assumed that late adverse effects would vary more in response to large partial volumes exposed to doses ranging from 101% to 107% than to very small partial volumes receiving >107%, for example. In the patients with any volumes receiving >107%, the median percentage volume of treated breast receiving dose >107% was extremely small (0.1%). This figure for partial breast volumes receiving >107% of prescribed dose is consistent with previous reports in the literature [28] . The distribution of volume receiving >100% dose was split into quartiles for the analysis assessing the effect of dosimetry on risk of late adverse effects. Logistic regression was used to assess the effect of breast size and dosimetry on the risk of any change in photographic breast appearance at 2 years. Each factor was first tested alone in a univariate model, and then both were included together to test whether the effects were independent of each other. Finally other factors associated with risk of late adverse effects (such as randomised radiotherapy fractionation regimen, surgical deficit, age, and adjuvant systemic therapy) were tested along with breast size and dosimetry in a multiple logistic regression analysis, and the final model retained those factors which were statistically significant.
Results
The FAST trial randomised 915 patients between October 2004 and March 2007 [24] . Although 16 out of 18 radiotherapy centres in the FAST trial used a CT planning system, only six centres had systems that allowed importation of data for joint analysis using Guiness software. (Royal Cornwall Hospital, Truro; The Royal Marsden Hospital, Sutton; Ipswich Hospital; Royal Shrewsbury Hospital; University Hospital of North Staffordshire, Stoke-onTrent and Beatson Oncology Centre, Glasgow). A total of 279 patients at these centres had baseline and 2-year photographs available for the analysis. The patient tumour and treatment characteristics of the study sample were representative of the FAST trial population as a whole (n = 915), see Table 1 . Age, time between surgery and randomisation, histological type, pathological tumour size, and tumour grade were comparable between the sample and the total FAST population. Adjuvant systemic therapy (endocrine treatment, usually tamoxifen 20 mg OD for 5 years) and axillary node sampling were used more frequently in the study sample than the total FAST population.
At 2 years post-randomisation, 201/279 (72%) women had no change in photographic breast appearance, 61 (22%) had mild change and 17 (6%) had marked change. The validity of photographic scores of breast size was confirmed in comparisons with breast volume data from the radiotherapy planning systems, see Fig. 2 . There was a statistically significant increase in measured breast volume across the three categories of breast size (p < 0.001), with a median of 778 cc in the small group, 1114 cc in medium and 1357 cc in large categories. Photographic scores of breast size in 279 (100%) patients were used for the analysis because data compatibility issues allowed absolute breast volume (cc) within the 50% isodose envelope to be estimated for only 171 (61%) women.
Breast size was significantly associated with volume receiving >100% of the prescribed dose; the median (interquartile range) volumes receiving >100% were 30.3% (22.7-37.3), 39.7% (33.7-45.3) and 38.1% (28.8-47.0) for small, medium and large breast categories, respectively (p < 0.001). Rates of any (mild or marked) change in photographic breast appearance at 2 years were highest (50%) in large-breasted women, 33% in the medium-breasted category and 21% in small-breasted patients. This trend was statistically significant in univariate analysis (p < 0.001 for trend; Table 2 ). Breast size remained a significant predictor when other significant risk factors (fractionation schedule and surgical deficit) and the dosimetry parameter were included in the multiple regression model (p = 0.006 for trend; Table 2 ). This confirmed breast size as an independent risk factor for radiation-induced change in breast appearance 2 years after radiotherapy using 3D dosimetry. Only 24% of patients received any dose >107% of prescribed dose, and there was no significant association with occurrence of late effects (chi-squared p = 0.64). The risk of any change in photographic breast appearance at 2 years increased with the proportion of breast volume receiving >100% of the prescribed dose (22% in the lowest and 39% in the highest quartiles, respectively), which was significant in univariate analysis (p = 0.009 for trend; Table 2 ). However, when breast size and other significant risk factors (fractionation schedule and surgical deficit) were included in the multiple regression model, the effect of dosimetry was no longer significant (p = 0.136 for trend; Table 2 ). This suggested that dose inhomogeneity, and other significant factors, left most of the effect of breast size on risk of late adverse effects unaccounted for, as indicated by odds ratios (95% CI) for medium and large breasts compared with small of 1.58 (0.83-3.00) and 3.87 (1.53-9.80), respectively, see Table 2 .
Discussion
Our data confirmed a significant association between breast size and dose inhomogeneity, in accordance with earlier literature [1, 2, 4, 6, 17] . It also confirmed breast size as a significant risk factor for change in photographic breast appearance, also consistent with a majority of published reports [2] [3] [4] [5] [6] [7] [8] [9] . The effect of dose inhomogeneity on late adverse effects of 2D-planned breast radiotherapy has been tested in two randomised trials. Donovan et al. [29] randomised 306 patients requiring adjuvant whole breast radiotherapy to 2D radiotherapy using standard wedge compensators or 3D intensity modulated radiotherapy using multiple static fields. The 2D-planned patients were 1.7 times more likely to have a change in breast appearance at 5 years, judged by change in photographic breast appearance (p = 0.008), an effect not reproduced at 2 years follow-up in a second trial [19] . Against our expectations, the present analysis failed to confirm residual dose inhomogeneity in patients planned and treated using 3D dosimetry as an independent risk factor for radiation-induced change in breast appearance.
We consider it unlikely that a major effect of residual dose inhomogeneity on risk of late effects in large-breasted patients treated in accordance with IUCC guidelines has been missed. The measure of breast size, although based on a categorical scale applied to clinical photographs, correlated with absolute breast size measured from 3D X-ray CT images of the breast in a subset (61%) of patients. Change in photographic appearance as an indicator of radiotherapy adverse effects has been well validated in randomised clinical trials conducted by our group, showing it to be sensitive to small (<10%) differences in randomised total dose [26, 27] . In the present study, 24% of patients received >107% of prescribed dose to an average partial breast volume of only 0.44%, so a correlation between patients receiving doses >107% and probability of late effects could not be expected.
Although breast size and dosimetry were each significantly associated with late effects of breast radiotherapy on univariate analysis, dosimetry was no longer significant when included in a multivariate model including breast size. However, breast size remained an independent significant predictor of late effects when included in a multivariate model along with fractionation schedule, surgical deficit and dosimetry. The inference is that breast size, not dosimetry, is the dominant risk factor for late effects following 3D planned breast radiotherapy.
Late effects in this study were assessed by scoring photographic breast appearance, using the contralateral breast to control for age-and weight-related changes. The effects of radiotherapy most easily noticed on photographs are changes in size and shape, with breast shrinkage the commonest effect. In large-or heavy-breasted women, the major component of the breast by volume is adipose tissue [30, 31] . This raises the possibility that adipose tissue in large-or heavy-breasted women is, in some way, more sensitive to the effects of radiotherapy. Whatever the mechanisms explaining why heavybreasted women are more likely to experience breast shrinkage and other late adverse effects, the challenge is to reduce treatment morbidity without negatively impacting on local control or survival rates. This report suggests that residual dose inhomogeneity in patients treated with optimal dosimetry is not able to negate the risk factor of large breast size. If confirmed by other studies, one implication would be to consider a small dose reduction to compensate for the enhanced risk of late adverse effects. A 10% reduction in total dose would reduce the absolute risk of late adverse effects at 2 years by 20%, assuming a c50 of 2 to describe the slope of the dose response curve at the 50% level of effect. In the setting of adjuvant breast radiotherapy, this dose reduction to whole breast would be associated with a 61% loss of local tumour control, assuming c95 of 0.2 at the 95% level of local tumour control [27, 32] .
Conclusion
Large-or heavy-breasted women are more likely than others to suffer change in breast size and shape after radiotherapy, even when 3D dosimetry has been optimised.
